Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026)
Gyre Therapeutics (GYRE) reported Share-based Compensation of $2.6 million for Q1 2026, up 409.47% year-over-year from $507000.0 in Q1 2025, and down 43.81% on a QoQ basis from $4.6 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Share-based Compensation data on file, last reported at $2.6 million in Q1 2026.
- Quarterly Share-based Compensation rose 409.47% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.2 million (up 595.78% YoY) and the FY2025 annual result came in at $7.2 million, up 761.25% from the prior year.
- Share-based Compensation slipped to $2.6 million in Q1 2026 per GYRE's latest filing, from $4.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.3 million in Q4 2022 and bottomed at $11000.0 in Q1 2024.
- The 5-year median for Share-based Compensation is $507000.0 (2025), against an average of $1.8 million.
- The widest annual swing landed in 2024, when Share-based Compensation plunged 94.76%; it then jumped 5562.5% in 2025.
- Tracing GYRE's Share-based Compensation over 5 years: stood at $12.3 million in 2022, then plunged by 43.95% to $6.9 million in 2023, then tumbled by 91.76% to $567000.0 in 2024, then jumped by 710.76% to $4.6 million in 2025, then sank by 43.81% to $2.6 million in 2026.
- Per Business Quant, the three latest GYRE Share-based Compensation figures stand at $2.6 million (Q1 2026), $4.6 million (Q4 2025), and $1.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 906,000.00 |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 6.88 Mn |
| Dec 31, 2023 | 6.88 Mn |
| Sep 30, 2023 | 98,000.00 |
| Sep 30, 2023 | 98,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 210,000.00 |
| Mar 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 12.28 Mn |
| Dec 31, 2022 | 12.28 Mn |
| Sep 30, 2022 | 224,000.00 |
| Sep 30, 2022 | 224,000.00 |
| Jun 30, 2022 | 346,000.00 |
| Jun 30, 2022 | 346,000.00 |
| Mar 31, 2022 | 515,000.00 |
| Mar 31, 2022 | 515,000.00 |
| Dec 31, 2021 | 683,000.00 |
| Dec 31, 2021 | 683,000.00 |
| Sep 30, 2021 | 713,000.00 |
| Sep 30, 2021 | 713,000.00 |
| Jun 30, 2021 | 983,000.00 |
| Jun 30, 2021 | 983,000.00 |
| Mar 31, 2021 | 1.03 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 920,000.00 |
| Dec 31, 2020 | 920,000.00 |
| Sep 30, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.07 Mn |
| Jun 30, 2020 | 834,000.00 |
| Jun 30, 2020 | 834,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Mar 31, 2020 | 805,000.00 |
| Dec 31, 2019 | 671,000.00 |
| Dec 31, 2019 | 671,000.00 |
| Sep 30, 2019 | 801,000.00 |
| Sep 30, 2019 | 801,000.00 |
| Jun 30, 2019 | 903,000.00 |
| Jun 30, 2019 | 903,000.00 |
| Mar 31, 2019 | 829,000.00 |
| Mar 31, 2019 | 829,000.00 |
| Dec 31, 2018 | 740,000.00 |
| Dec 31, 2018 | 740,000.00 |
| Sep 30, 2018 | 702,000.00 |
| Sep 30, 2018 | 702,000.00 |
| Jun 30, 2018 | 551,000.00 |
| Jun 30, 2018 | 551,000.00 |
| Mar 31, 2018 | 606,000.00 |
| Mar 31, 2018 | 606,000.00 |
| Dec 31, 2017 | 307,000.00 |
| Dec 31, 2017 | 307,000.00 |
| Sep 30, 2017 | 325,000.00 |
| Sep 30, 2017 | 325,000.00 |
| Jun 30, 2017 | 111,000.00 |
| Jun 30, 2017 | 111,000.00 |
| Mar 31, 2017 | 120,000.00 |
| Mar 31, 2017 | 120,000.00 |
| Dec 31, 2016 | 130,000.00 |
| Dec 31, 2016 | 130,000.00 |
| Sep 30, 2016 | 188,000.00 |
| Sep 30, 2016 | 188,000.00 |
| Jun 30, 2016 | 165,000.00 |
| Jun 30, 2016 | 165,000.00 |
| Mar 31, 2016 | 153,000.00 |
| Mar 31, 2016 | 153,000.00 |
| Dec 31, 2015 | 191,000.00 |
| Dec 31, 2015 | 191,000.00 |
| Sep 30, 2015 | 52,000.00 |
| Sep 30, 2015 | 52,000.00 |
| Jun 30, 2015 | 41,000.00 |
| Jun 30, 2015 | 41,000.00 |
| Mar 31, 2015 | 44,000.00 |
| Mar 31, 2015 | 44,000.00 |
| Dec 31, 2014 | 55,000.00 |
| Dec 31, 2014 | 55,000.00 |
| Sep 30, 2014 | 56,000.00 |
| Sep 30, 2014 | 56,000.00 |
| Jun 30, 2014 | 464,000.00 |
| Jun 30, 2014 | 464,000.00 |
| Mar 31, 2014 | 825,000.00 |
| Mar 31, 2014 | 825,000.00 |
| Dec 31, 2013 | -3.86 Mn |
| Dec 31, 2013 | -3.86 Mn |
| Sep 30, 2013 | 682,000.00 |
| Sep 30, 2013 | 682,000.00 |
| Jun 30, 2013 | 655,000.00 |
| Jun 30, 2013 | 655,000.00 |
| Mar 31, 2013 | 1.61 Mn |
| Mar 31, 2013 | 1.61 Mn |
| Dec 31, 2012 | 1.38 Mn |
| Dec 31, 2012 | 1.38 Mn |
| Sep 30, 2012 | 889,000.00 |
| Sep 30, 2012 | 889,000.00 |
| Jun 30, 2012 | 2.07 Mn |
| Jun 30, 2012 | 2.07 Mn |
| Mar 31, 2012 | 1.92 Mn |
| Mar 31, 2012 | 1.92 Mn |
| Dec 31, 2011 | 2.00 Mn |
| Dec 31, 2011 | 2.00 Mn |
| Sep 30, 2011 | 905,000.00 |
| Sep 30, 2011 | 905,000.00 |
| Jun 30, 2011 | 943,000.00 |
| Jun 30, 2011 | 943,000.00 |
| Mar 31, 2011 | 2.16 Mn |
| Mar 31, 2011 | 2.16 Mn |
| Dec 31, 2010 | 1.23 Mn |
| Dec 31, 2010 | 1.23 Mn |
| Sep 30, 2010 | 624,000.00 |
| Sep 30, 2010 | 624,000.00 |
| Jun 30, 2010 | 493,000.00 |
| Jun 30, 2010 | 493,000.00 |